Microsatellite instability (MSI) is a phenotype originated from an impaired DNA mismatch repair (MMR) system and is closely related to a broad range of tumors, including gastric, endometrial and colorectal cancers. The analysis of MSI status is of growing relevance as tumors positive for MSI are more sensitive to immunotherapy.
The Human Target-Microsatellite Instability Plus (HT-MSI+) Kit uses fluorescent multiplex PCR to evaluate the MSI status from DNA samples of any source. HT-MSI+ analyses an expanded panel of 6 quasimonomorphic mononucleotide markers, including the five standard NR-27, NR-21, NR-24, BAT-25, BAT-26 mononucleotide repeats plus the HSP110 microsatellite T17 (mononucleotide repeat retained in intron 8), whose mutation has been highly associated with MSI positive colorectal carcinomas[3,4].
HT-MSI+ analysis can be carried out on tumor cells without the need of a reference DNA sample, which facilitates a simpler experimental setup and allows for an increased number of target samples on the plate.
Figure 1: Workflow HT-MSI+ assay based on a multiplex PCR followed by Fragment Analysis
Please contact Dr. Larissa Consani Textor with all questions or inquiries you may have!
 Chang et al. (2018) Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Appl Immunohistochem. Mol. Morphol. 26 (2):e15-e21.
 Goel et al. (2010) An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One 5 (2): e9393.
 Dorard et al. (2011) Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat. Med. 17:1283.
 Berardinelli et al. (2018) Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients. Oncotarget 9 (47):28691.